Neuland Laboratories Limited has informed the Exchange about Investor Presentation
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported exceptional Q4FY26 results with Total Income of Rs. 788.7 crore (up 134.9% YoY) and EBITDA of Rs. 319.4 crore (up 448.6% YoY), with EBITDA margin expanding sharply to 40.5% from 17.3% in Q4FY25. For the full year FY26, Total Income reached Rs. 2,053.1 crore (up 37.1% YoY) with EBITDA of Rs. 603.4 crore (up 76% YoY) and EBITDA margin at 29.4% (improved by 650 bps YoY). PAT for FY26 was Rs. 363.1 crore (up 40% YoY). The company maintained a net cash position with Net Debt at Rs. (156.8) crore. Capex outflow was Rs. 397 crore in FY26. CMS business showed strong growth driven by commercial molecules, while peptide manufacturing investments are proceeding as planned. Two new DMFs were filed for Vonoprazan and Edoxaban.
The sharp margin expansion and strong profit growth indicate operating leverage from CMS scale-up. The company is transitioning from high-cost development projects to commercial production, which is positive for profitability. The negative net debt position provides financial flexibility for future growth investments.